Aytu Biopharma (AYTU) Update / Briefing June 11, 2025 04:30 PM ET Speaker0 Greetings. Welcome to the Aytu BioPharma Analyst and Investor Conference Call, ExuA Opportunity and Commercialization Plan. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I will now turn the conference over to your host, Robert Blum with Lytham Partners. You may begin. Speaker1 Thank you very much, John. Good a ...

Aytu Biopharma (AYTU) Q3 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Robert Blum - Managing PartnerJosh Disbrow - Chief Executive OfficerRyan Selhorn - CFO Conference Call Participants Naz Rahman - Analyst Operator Please note this conference is being recorded. I will now turn the conference over to your host, Robert Blum, Investor Relations at Robert, your line, you may begin. Robert Blum Thank you very much, and good afternoon, everyone. As the operator indicated, during today's call, ...

Aytu Biopharma (AYTU) Q3 2025 Earnings Call May 14, 2025 04:30 PM ET Speaker0 Please note this conference is being recorded. I will now turn the conference over to your host, Robert Blum, Investor Relations at Robert, your line, you may begin. Speaker1 Thank you very much, and good afternoon, everyone. As the operator indicated, during today's call, we will be discussing Aytu BioPharma's fiscal twenty twenty five third quarter operational and financial results for the period ended 03/31/2025. With us on tod ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ Commission File Number: 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) | Delaware | 47-0883144 | | --- | ...

Exhibit 99.1 Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectively Adjusted EBITDA1 of $3.9 million Total net revenue of $18.5 million up 32% year-over-year Company to host conference call and webcast today, May 14, 2025, at 4:30 p.m. Eastern time DENVER, CO / May 14, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for th ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Josh Disbrow - Chief Executive Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Good day, everyone, and welcome to the Aytu BioPharma Fiscal 2025 Q2 Earnings Call. At this time, all participants have been placed on a listen-only. [Operator Instructions] It is now my pleasure to turn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ Commission File Number: 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) | Delaware | 47-0883144 | | -- ...

Exhibit 99.1 Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results Net income of $0.8 million Adjusted EBITDA1 of $1.3 million Pediatric Portfolio net revenue up 86% sequentially First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023 $20.4 million cash balance at December 31, 2024 Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time Consumer Health – Discontinued Operations DENVER, ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Outgoing Chief Financial Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2025 Q1 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ Commission File Number: 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) (Address of principal executi ...